EGFR and neoplasm: Additional tumor material is required for interrogating predictive biomarkers, using IHC (e.g., ALK, ROS1, PD-L1), in situ hybridization (ISH; e.g., ALK, ROS1) or sequencing techniques (e.g., EGFR, BRAF V600E, etc.).